Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Helen L, MD
16 Oktoba 2021 11:14:30
Diclofenac kwa mjamzito
Diclofenac ni dawa jamii ya NSAID, inayotumika kutibu athraitizi, maumivu makali na sugu na maumivu ya hedhi. Dawa jamii hii pia huwa na uwezo wa kushusha homa. Diclofenac ipo kwenye kundi moja na dawa zingine kama indomethacin, sulindac, na tolmetin.
Kufunga kwa mshipa wa ductus arteriosus kwa mtoto aliye tumboni ni moja ya madhara ya matumizi ya diclofenac wakati wa ujauzito. Tukio hili hutokana na uwezo wa diclofenac kuzuia uzalishaji wa Prostaglandin.
Matumizi ya diclofenac wakati wa ujauzito pia huzuia uchungu, na kupunguza utendaji kazi wa figo za mtoto sawa na tendo linalofanywa na dawa indomethacin. Matokeo ya kufunga kwa mshipa dactus arteriosus ni mtoto kupata shinikizo endelevu kwenye mapafu kama dawa itatumika kipindi cha 3 cha ujauzito karibia na wakati wa kujifungua.
Wanawake wanaotarajia kubeba mimba wanashauriwa kutotumia dawa zinazozuia uzalishaji wa prostaglandin ikiwa pamoja na diclofenac, kwa kuwa imeonekana kwenye tafiti za wanyama kuzuia kiini kupandikizwa kwenye kuta ya ndani ya kizazi na hivyo kuzuia ujauzito kuendelea.
Hata hivyo dawa jamii ya NSAIDs zimeonekana kuhusiana na mimba kutoka na ulemavu wa kuzaliwa, licha ya hatari yake kuwa kidogo.
Matumizi wakati wa ujauzito
Taarifa za binadamu zinaonyesha hatari kwenye kipindi cha kwanza na tatu cha ujauzito
Ushahidi wa matumizi ya indomethacine au dawa zingine zinazofanana nayo kwenye ujauzito zinaonekana kuwa ni sumu kwa ukuaji wa tumboni kwa kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo cha kichanga au kijusi tumboni katika kipindi cha kwanza na cha tatu tu cha ujauzito lakini si katika kipindi cha pili. Taarifa za madhara ya dawa hii kwa binadamu zinamashiko zaidi kuliko taarifa za tafiti kwa wanyama.
Matumizi wakati wa kunyonyesha
Hakuna (zipo chache) taarifa za binadamu- Inaweze patana na unyonyeshaji.
Hakuna taarifa za uzoefu kuhusu matumizi ya dawa hii kwa mama anayenyonyesha au kuna taarifa chache. Taarifa chache zilizopo zinaonyesha kuwa dawa hii haiwasilishi hatari yenye mashiko kwa kichanga anayenyonya maziwa ya mama anayetumia dawa.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 19:39:23
Rejea za mada hii;
1. Levin DL. Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation. Semin Perinatol 1980;4:35–44.
2. Van Marter LJ, et al.Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics 1996;97:658–63.
3. Matt DW, et al. Toxic effects on the female reproductive system during pregnancy, parturition, and lactation. In: Witorsch RJ, ed. Reproductive Toxicology. 2nd ed. New York, NY: Raven Press, 1995:175–93.
4. Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol 1993;169:1255–65.
5. Product information. Voltaren. Geigy Pharmaceuticals, 1995.
6. Carp HJA, et al. Effect of diclofenac on implantation and embryonic development in the rat. Eur J Obstet Gynecol Reprod Biol 1988;28:273–7.
7. Montenegro MA, et al. Induction of cleft palate in mice by inhibitors of prostaglandin synthesis. J Craniofac Genet Del Biol 1990;10:83–94.
8. Cabrol D, et al. Induction of labor and cervical maturation using mifepristone (RU 486) in the late pregnant rat. Influence of a cyclooxygenase inhibitor (diclofenac). Prostaglandins 1991;42:71–9.
9. Siu SSN, et al. A study on placental transfer of diclofenac in first trimester of human pregnancy. Hum Reprod 2000;15:2423–5.
10. Royburt M, et al. Non-traumatic rupture of kidney in pregnancy—case report and review. Acta Obstet Gynecol Scand 1994;73:663–7.
11. Nielsen GLet al. Risk of adverse birth outcome and miscarriage in pregnant users of nonsteroidal antiinflammatory drugs: population based observational study and case-control study. Br Med J 2001;322:266–70.
12. Ericson A, et al. Nonsteroidal antiinflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371–5.
13. Li DK, et al. Exposure to nonsteroidal antiinflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. Br Med J 2003;327:368–71.
14. Tassinari MS, et al. NSAIDs and developmental toxicity. Birth Defects Res (Part B) 2003;68:3–4.
15. Kallen BAJ, et al. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255–61.
16. Ofori B, et al. Risk of congenital anomalies in pregnant users of nonsteroidal antiinflammatory drugs: a nested case-control study. Birth Defects Res (Part B) 2006;77:268–79.
17. Adverse Drug Reactions Advisory Committee. Premature closure of the fetal ductus arteriosus after maternal use of nonsteroidal antiinflammatory drugs. Med J Aust 1998;169:270–1.
18. Zenker M, et al. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. J Perinat Med 1998;26:231–4.
19. Siu KL, et al. Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension. J Paediatr Child Health 2004;40:152–3.
20. Anderson PO. Medication use while breast feeding a neonate. Neonatal Pharmacol Q 1993;2:3–14.
21. Goldsmith DP. Neonatal rheumatic disorders. View of the pediatrician. Rheum Dis Clin North Am 1989;15:287–305.
22. Needs CJ, et al. Antirheumatic medication during lactation. Br J Rheumatol 1985;24:291–7.